Inaugural gathering on November 5, 2026, marks the launch of a lasting partnership between Health Union and DTC Perspectives to unite biopharma marketing leaders, elevate rare disease strategy, and address critical commercial, technical, and patient engagement shifts.
PHILADELPHIA, Sept. 22, 2026 /PRNewswire/ — Health Union, the leader in online health communities, and DTC Perspectives, the premier conference and publishing company for consumer health marketers, today announced their inaugural joint venture: The Rare Marketing Summit: Redefining the Commercial Model for Rare Disease.
A Landmark Partnership to Advance Rare Disease Marketing and Redefine Precision Commercial Strategies
This inaugural gathering marks the launch of a lasting strategic partnership between Health Union and DTC Perspectives. Designed as a dedicated platform for rare disease and niche oncology marketers, the collaboration brings together Health Union’s deep patient and HCP engagement capabilities with DTC Perspectives’ executive marketing network to establish a continuous forum for promoting innovation, peer collaboration, and commercial excellence, specific to the unique needs of these therapeutic areas.
The exclusive, invitation-only summit will take place onThursday, November 5, 2026, from 10:00 AM to 4:00 PM at The Westin Copley Place in Boston, MAwith a cocktail reception to follow.
Fostering Innovation & Collaboration Among Rare Marketers
As medicine becomes increasingly specialized, the rare disease and niche oncology pipelines have emerged as the primary growth engine for the biopharma industry. However, traditional commercial playbooks fall short in hyper-targeted markets. By uniting their shared strengths, Health Union and DTC Perspectives are uniquely positioned to help biopharma marketers navigate these high-stakes challenges – from identifying ultra-small patient populations and activating generalist physicians to building high-touch caregiver experiences and collaborating with advocacy ecosystems.
Designed specifically for senior-level biopharma marketing leaders, this collaborative summit skips broad, surface-level presentations to focus on actionable, real-world strategies across six key topics:
- Diagnostic Acceleration: Commercial and technical strategies to shorten the diagnostic journey.
- Regulatory Compliance: Evolving FDA risk-disclosure standards across targeted marketing channels.
- DTC & Data Strategy: AI targeting, CTV channel expansion, and micro-audience analytics to activate precision audiences.
- Patient & Caregiver Experience: The role of high-touch, personalized journeys, community activation, and adherence support.
- Re-Engineered HCP Strategy: Generalist symptom recognition and sales force white-space coverage.
- Advocacy & Ecosystems: Maximizing non-profit partnerships alongside patient support networks.
“Commercializing a rare disease therapy requires a fundamental departure from mass-market pharma strategies, which is why we are so delighted to partner with DTC Perspectives for this inaugural event,” said Olivier Chateau, Co-Founder and CEO of Health Union. “This joint venture reflects our shared, ongoing commitment to the rare disease community. By combining Health Union’s deep community connections with DTC Perspectives’ premier executive reach, we are taking the first step in a lasting partnership to help marketers reach and support these critical, underserved audiences.”
“We are thrilled to join forces with Health Union for this milestone collaboration,” added Bob Ehrlich, CEO of DTC Perspectives. “Bringing together our complementary strengths allows us to offer biopharma leaders an unprecedented, peer-to-peer environment. This summit is just the beginning of our joint efforts to provide marketers with novel opportunities to exchange proven approaches for AI targeting, non-specialist HCP engagement, and authentic advocacy alignment in the rare disease space.”
The Future of the Partnership: Dedicated Workshop & Awards Ceremony in June 2027
The November summit in Boston represents only the first milestone in this collaborative effort. Building on the momentum of this inaugural gathering, Health Union and DTC Perspectives will expand their rare disease initiative with a dedicated Rare Disease Workshop and Awards Ceremony in June 2027, featured as an official extension of the annual DTC National Conference. This ongoing extension will serve as a premier stage to celebrate breakthroughs, honor pioneering marketers, and deepen industry-wide collaboration year after year.
Attendance for the November 5 event is strictly capped to preserve the intimacy of executive peer exchange. Invited biopharma leaders can request registration details at https://go.dtcperspectives.com/rare-marketing-summit.
Health Union powers the first and largest community-based activation and data platform, transforming healthcare by providing unparalleled support, information, and validation for millions navigating complex health conditions and their care teams. With over 125 condition-specific online communities and 15 years of digital health leadership, Health Union’s authentic engagements fuel the company’s robust suite of endemic media, influencer marketing, market research, and data solutions, driving proven outcomes for patients, HCPs, and brands. Go to www.health-union.com to learn more.
DTC Perspectives, Inc. has been the leader in the direct-to-consumer marketing of pharmaceuticals and medical devices since 2001. Founded by Robert Ehrlich, the former VP Consumer Marketing for Parke-Davis, DTC Perspectives focuses on the emerging consumer desire for health information. Each year the DTC National Conference brings together marketers, their agencies, and media companies to discuss the latest in DTC Marketing. DTC Perspectives also consults, publishes studies, and represents the industry on important issues. Go to www.dtcperspectives.com to learn more.
View original content to download multimedia:https://www.prnewswire.com/news-releases/health-union-and-dtc-perspectives-announce-executive-rare-disease-marketing-summit-302885842.html
The articles, information, and content displayed on this webpage may
include materials prepared and provided by third parties. Such
third-party content is offered for informational purposes only and
is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the
accuracy, completeness, timeliness, or reliability of any third-party
content displayed on this site. The views and opinions expressed in
third-party content are those of the respective authors and do not
necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays
in this content, nor for any actions taken in reliance thereon.
Users are advised to exercise their own judgment and seek independent
financial advice before making any decisions based on such content.
The third-party providers of this content are not affiliated with
Morningstar, and their inclusion on this site does not imply any
form of partnership, agency, or endorsement.
Trading at a 21% discount, this wide-moat stock is a rare find.
Malik Ahmed Khan, CFASep 17, 2026
Plus, stocks we do and don’t like after earnings.
David Sekera, CFA and Susan DziubinskiSep 21, 2026
Plus, nine bond ETFs that Morningstar analysts like.
Daniel Sotiroff and Ivanna HamptonSep 18, 2026The stocks of these high-quality companies look cheap today.
Tori BrovetSep 11, 2026Index investing can be risky—take it from me, I’m an indexer.
Dan LefkovitzSep 16, 2026
